-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Valproic acid-[d15]
Category | Human immunodeficiency Virus (HIV) |
CAS | 362049-65-8 |
Description | One of the isotopic labelled form of Valproic Acid, which could be used as an antiepileptic agent. |
Product Information
Synonyms | 2-Propylpentanoic-d15 Acid; Dipropylacetic Acid-d15; 2-Propylvaleric Acid-d15 |
IUPAC Name | 2,3,3,4,4,5,5,5-octadeuterio-2-(1,1,2,2,3,3,3-heptadeuteriopropyl)pentanoic acid |
Molecular Weight | 159.30 |
Molecular Formula | C8HD15O2 |
Canonical SMILES | CCCC(CCC)C(=O)O |
InChI | InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)/i1D3,2D3,3D2,4D2,5D2,6D2,7D |
InChIKey | NIJJYAXOARWZEE-BKUSUEPDSA-N |
Boiling Point | 220.0°C at 760 mmHg |
Flash Point | 116.6°C |
Purity | 95% by HPLC; 98% atom D |
Density | 0.9±0.1 g/cm3 |
Solubility | In vitro: 10 mM in DMSO |
Appearance | Solid powder |
Storage | Store at -20°C |
Index Of Refraction | 1.435 |
In Vitro | Valproic acid (VPA) (0-15 mM; 24 and 72 h) inhibits Hela cell growth in a dose- and time- dependent manner. Valproic acid (10 mM; 24 h) significantly attenuates the activities of total, cytosol and nuclear HDACs. Valproic acid (0-15 mM; 24 h) induces a G1 phase arrest at 1-3 mM and a G2/M phase arrest at 10 mM, and increases the percentage of sub-G1 cells in HeLa cells. Valproic acid also induces necrosis, Apoptosis and Lactate dehydrogenase (LDH) release. Valproic acid (0-20 mM; 24 h) activates Tcf/Lef-dependent transcription and synergizes with lithium. Valproic acid (0-5 mM; 0-18 h) increases β-catenin levels in Neuro2A cells. Valproic acid (0-2 mM; 0-24 h) stimulates phosphorylation of AMPK and ACC in hepatocytes. Valproic acid (0-10 mM; 2 days) induces Notch1 signaling and morphologic differentiation, suppresses production of NE tumor markers in SCLC cells. |
In Vivo | Valproic acid (VPA) (500 mg/kg; i.p.; daily for 12 days) inhibits tumor angiogenesis in mice transplanted with Kasumi-1 cells. Valproic acid (350 mg/kg; i.p.; once) enhances social behavior in rats. Valproic acid (0.26% (w/v); p.o. via drinking water; 14 days) decreases liver mass, hepatic fat accumulation, and serum glucose in obese mice without hepatotoxicity. |
PSA | 37.30000 |
Target | HDAC; Autophagy; Mitophagy; HIV; Notch; Endogenous Metabolite |